Key Takeaways:
- PRAGMA Therapeutics is a leading French neuroscience biotech startup focused on the discovery and development of proprietary small molecule therapeutics for the treatment of stress-related diseases.
- They are specifically targeting metabotropic glutamate receptors, making their approach unique and innovative.
- PRAGMA aims to rapidly correlate in-vivo proof-of-concept studies with target engagement and pharmacodynamic biomarkers in humans to increase their success rate in clinical trials.
Is Neuroscience Biotech revolutionising treatment for Stress-Related Disorders in France? Determining if this statement is true is best illustrated by the strides taken by PRAGMA Therapeutics, a Saint-Julien-en-Genevois, Rhone-Alpes-based Biotech company. Founded in 2015 by Guillaume Duvey and Sylvain Celanire, PRAGMA, a prestigious player in the Biotechnology, Health Care, Pharmaceutical, and Therapeutics industries in France, has been making significant strides in their innovative approach to handling stress disorders.
PRAGMA’s focus has been on discovering and developing proprietary small molecule therapeutics for the treatment of stress-related diseases, particularly Post-Traumatic Stress Disorders (PTSD), and hearing loss. This noble endeavour is backed by a flexible organization spearheaded by a competent team possessing world-leading expertise in neuroscience drug development.
The uniqueness of PRAGMA Therapeutics lies in their innovative approach to treating stress-related responses, fear, cognitive dysfunctions linked to PTSD, as well as acute and acoustic trauma-induced hearing loss. This approach involves targeting a specific class of G-protein-coupled receptors (GPCR), the metabotropic glutamate receptors family (mGluRs). Currently, PRAGMA is developing allosteric modulators of the mGlu7 subtype, integrating the new standards of drug development into their strategy. This particular focus sets PRAGMA apart from other biotech startups and demonstrates their forward-thinking approach.
The team at PRAGMA believes in the potential of pharmacodynamic biomarkers to predict the outcome of clinical trials. Hence, they aim to rapidly correlate in-vivo proof-of-concept studies with the target engagement and these biomarkers in humans. This integration is designed to boost their clinical trial success rate and actualize their mission of providing novel solutions to stress-related disorders faster.
Witnessing the growth and innovative approach of PRAGMA Therapeutics brings optimism to the future of treatment for stress-related disorders in France, and possibly globally. If their targeted approach yields the desired results, it could revolutionise not just the biotechnology industry in France, but the global understanding and treatment of stress-related disorders. This revolution would bring about a drastic change in the healthcare industry, providing relief to millions suffering from these diseases.
For more about PRAGMA Therapeutics and their innovative approach to treating stress-related disorders, visit their website, follow them on Twitter, or connect with them on Linkedin.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
